Divi's Lab.
Drug Manufacturers - Specialty & Generic · DIVISLAB
Mega CapHealthcareHigh Growth
Dr. Murali K. Divi
Managing Director · Visionary
Company DNA
Founder-Centric
About
Divi's Lab. is a Mega Cap company in the Healthcare sector, listed on NSE as DIVISLAB. With a market cap of ₹168K Cr and revenue of ₹9K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Dr. Murali K. Divi's personal expertise and technical vision remain the central pillar of the company's research-led business model. Its strategic mandate: Maintaining a leadership position in global APIs requires sustained R&D investment and a focus on complex, niche molecule development.
FAQ
What kind of company is Divi's Lab.?
Divi's Lab. is a Mega Cap Healthcare company (DIVISLAB) in the High Growth phase with a market cap of ₹168K Cr. It is classified as Founder-Centric in culture.
What is Divi's Lab.'s culture and work environment like?
Divi's Lab. has a Founder-Centric culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Dr. Murali K. Divi's personal expertise and technical vision remain the central pillar of the company's research-led business model.
Who leads Divi's Lab.?
Divi's Lab. is led by Dr. Murali K. Divi (Managing Director), a Visionary leader with 40 years of experience.
What are Divi's Lab.'s financials?
Divi's Lab. reported revenue of ₹9K Cr in FY25 with a 5-year revenue CAGR of 2%. Operating margin: 27.6%. Market cap: ₹168K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleHigh Growth
Dr. Murali K. Divi's personal expertise and technical vision remain the central pillar of the company's research-led business model.
Mandate
Maintaining a leadership position in global APIs requires sustained R&D investment and a focus on complex, niche molecule development.
Maintaining a leadership position in global APIs requires sustained R&D investment and a focus on complex, niche molecule development.
Financials
Revenue FY25₹9K Cr
PAT FY25₹2K Cr
Rev CAGR 5Y2%
OPM27.6%
NPM23.5%
ROE14.6%
ROCE16.6%
P/E64.9
Fwd P/E51.9
P/B10.5
D/E0.6
Mkt Cap₹168K Cr
Promoter52.1%
Institutional28.9%
Similar Culture
Could You Lead Divi's Lab.?
Take the Genome Benchmark →